𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial

✍ Scribed by Stone, G. W.; Midei, M.; Newman, W.; Sanz, M.; Hermiller, J. B.; Williams, J.; Farhat, N.; Caputo, R.; Xenopoulos, N.; Applegate, R.; Gordon, P.; White, R. M.; Sudhir, K.; Cutlip, D. E.; Petersen, J. L.

Book ID
126193545
Publisher
Lippincott Williams and Wilkins
Year
2009
Tongue
English
Weight
436 KB
Volume
119
Category
Article
ISSN
0009-7322

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Comparison of Everolimus-Eluting and Pac
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa πŸ“‚ Article πŸ“… 2010 πŸ› American College of Cardiology 🌐 English βš– 939 KB
Meta-analysis of everolimus-eluting vers
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical evaluation of the Xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)
✍ Dangas, George D. (author);Serruys, Patrick W. (author);Kereiakes, Dean J. (auth πŸ“‚ Article πŸ“… 2013 πŸ› American College of Cardiology 🌐 English βš– 522 KB
Meta-analysis of everolimus-eluting vers
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical evaluation of the Xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)
✍ Dangas, George D. (author);Serruys, Patrick W. (author);Kereiakes, Dean J. (auth πŸ“‚ Article πŸ“… 2013 πŸ› American College of Cardiology 🌐 English βš– 522 KB
Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat